Squamous cell carcinoma - Сквамозен Карцином
☆ Во резултатите на Stiftung Warentest од Германија за 2022 година, задоволството на потрошувачите со ModelDerm беше само малку помало отколку со платените консултации за телемедицина.
Squamous cell carcinoma well differentiated ― Забележана е соседна актинична кератоза.
References
Squamous cell carcinoma (SCC) е втор најчест карцином на кожа во Соединетите Држави, по basal cell carcinoma. Обично започнува од преканцерозни лезии наречени actinic keratosis и може да се прошири на други делови од телото. Главната причина е изложеноста на ултравиолетово (УВ) зрачење од сонцето, кое се акумулира со текот на времето. Третманот обично вклучува хируршко отстранување, особено за SCC на главата и вратот. Терапијата со зрачење е опција за постари пациенти или оние кои не можат да имаат операција. Имуносупресијата го зголемува ризикот од SCC. Иако ретко, SCC може да се шири, особено кај пациенти со ослабен имунолошки систем. Редовните прегледи и заштитата од сонце се важни за оние со SCC.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.
Cutaneous squamous cell carcinoma (CSCC) е вториот најчест карцином кај луѓето, а неговиот број расте. Иако CSCC обично покажува бенигно клиничко однесување, тој може да се прошири и локално и на други делови од телото. Научниците идентификуваа специфични патишта вклучени во развојот на CSCC, што доведува до нови третмани. Високиот број на мутации и зголемениот ризик кај имуносупримирани пациенти го поттикнаа развојот на имунотерапија. Овој преглед ги разгледува генетските корени на CSCC и најновите третмани насочени кон специфични молекули и имунолошкиот систем.
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors
○ Дијагноза и третман
#Dermoscopy
#Skin biopsy